Susquehanna International Group’s XTL Biopharmaceuticals XTLB Stock Holding History

Susquehanna International Group’s Portfolio XTLB Stock Details XTLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,448	Closed	-$85K	–	10110
2018 Q3	$85K	Buy	10,448 +278	+3%	+$2.03K	﹤0.01%	8662
2018 Q2	$75K	Buy	+10,170	New	+$76.3K	﹤0.01%	9155
2017 Q4	–	Sell	-2,888	Closed	-$27K	–	10006
2017 Q3	$27K	Buy	+2,888	New	+$34K	﹤0.01%	8619

Other funds holding XTLB

Noked Capital Tel Aviv, Israel $946K AUM 17.1% 1-Year Est. Return

Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Susquehanna International Group's XTLB Position: Q4 2018 in Review

Susquehanna International Group sold out of XTL Biopharmaceuticals (XTLB) in Q4 2018, closing a stake of 10,448 shares — an estimated $85K sold.

Susquehanna International Group first reported a position in XTLB in Q3 2017 and held it in 3 quarters. The position peaked at $85K in Q3 2018. 6 funds tracked by Wall St. Rank hold XTLB as of Q4 2018.

Susquehanna International Group reported no remaining XTL Biopharmaceuticals position as of Q4 2018 after selling out during the quarter.
Susquehanna International Group sold 10,448 XTL Biopharmaceuticals shares in Q4 2018, an estimated $85K.
Susquehanna International Group first reported a position in XTL Biopharmaceuticals in Q3 2017 and held it in 3 quarters.
Susquehanna International Group's XTL Biopharmaceuticals position peaked at $85K in Q3 2018.
6 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q4 2018.

Based on Susquehanna International Group's 13F filing for Q4 2018, filed 14 Feb 2019.